These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 32104476)

  • 1. Nanocarriers as a powerful vehicle to overcome blood-brain barrier in treating neurodegenerative diseases: Focus on recent advances.
    Niu X; Chen J; Gao J
    Asian J Pharm Sci; 2019 Sep; 14(5):480-496. PubMed ID: 32104476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current insights on lipid nanocarrier-assisted drug delivery in the treatment of neurodegenerative diseases.
    Teixeira MI; Lopes CM; Amaral MH; Costa PC
    Eur J Pharm Biopharm; 2020 Apr; 149():192-217. PubMed ID: 31982574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Research Progress of Nanocarriers for the Treatment of Alzheimer's Disease.
    Li L; Zhang J; Huang X; Du J; Tu Z; Wu H; Liu X; Yuan M
    Curr Pharm Des; 2023; 29(2):95-115. PubMed ID: 36529920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A review of the potential role of nano-enabled drug delivery technologies in amyotrophic lateral sclerosis: lessons learned from other neurodegenerative disorders.
    Mazibuko Z; Choonara YE; Kumar P; Du Toit LC; Modi G; Naidoo D; Pillay V
    J Pharm Sci; 2015 Apr; 104(4):1213-29. PubMed ID: 25559087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strategic nanocarriers to control neurodegenerative disorders: Concept, challenges, and future perspective.
    Ashique S; Afzal O; Yasmin S; Hussain A; Altamimi MA; Webster TJ; Altamimi ASA
    Int J Pharm; 2023 Feb; 633():122614. PubMed ID: 36646255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanoparticle-mediated brain drug delivery: Overcoming blood-brain barrier to treat neurodegenerative diseases.
    Saraiva C; Praça C; Ferreira R; Santos T; Ferreira L; Bernardino L
    J Control Release; 2016 Aug; 235():34-47. PubMed ID: 27208862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo biodistribution of prion- and GM1-targeted polymersomes following intravenous administration in mice.
    Stojanov K; Georgieva JV; Brinkhuis RP; van Hest JC; Rutjes FP; Dierckx RA; de Vries EF; Zuhorn IS
    Mol Pharm; 2012 Jun; 9(6):1620-7. PubMed ID: 22536790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent progress of drug nanoformulations targeting to brain.
    Khan AR; Yang X; Fu M; Zhai G
    J Control Release; 2018 Dec; 291():37-64. PubMed ID: 30308256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of Iron Oxide Nanoparticles in the Diagnosis and Treatment of Neurodegenerative Diseases With Emphasis on Alzheimer's Disease.
    Luo S; Ma C; Zhu MQ; Ju WN; Yang Y; Wang X
    Front Cell Neurosci; 2020; 14():21. PubMed ID: 32184709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of neurodegenerative disorders through the blood-brain barrier using nanocarriers.
    Poovaiah N; Davoudi Z; Peng H; Schlichtmann B; Mallapragada S; Narasimhan B; Wang Q
    Nanoscale; 2018 Sep; 10(36):16962-16983. PubMed ID: 30182106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances with liposomes as drug carriers for treatment of neurodegenerative diseases.
    Seo MW; Park TE
    Biomed Eng Lett; 2021 Aug; 11(3):211-216. PubMed ID: 34350048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances in Bio-conjugated nanocarriers for crossing the Blood-Brain Barrier in (pre-)clinical studies with an emphasis on vesicles.
    Poustforoosh A; Nematollahi MH; Hashemipour H; Pardakhty A
    J Control Release; 2022 Mar; 343():777-797. PubMed ID: 35183653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surface-modified lipid nanocarriers for crossing the blood-brain barrier (BBB): A current overview of active targeting in brain diseases.
    Teixeira MI; Lopes CM; Amaral MH; Costa PC
    Colloids Surf B Biointerfaces; 2023 Jan; 221():112999. PubMed ID: 36368148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strategies of Engineering Nanoparticles for Treating Neurodegenerative Disorders.
    Nguyen KT; Pham MN; Vo TV; Duan W; Tran PH; Tran TT
    Curr Drug Metab; 2017; 18(9):786-797. PubMed ID: 28124594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liposomes for Targeted Delivery of Active Agents against Neurodegenerative Diseases (Alzheimer's Disease and Parkinson's Disease).
    Spuch C; Navarro C
    J Drug Deliv; 2011; 2011():469679. PubMed ID: 22203906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PLGA-Based Nanoparticles for Neuroprotective Drug Delivery in Neurodegenerative Diseases.
    Cunha A; Gaubert A; Latxague L; Dehay B
    Pharmaceutics; 2021 Jul; 13(7):. PubMed ID: 34371733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current Limitations in the Treatment of Parkinson's and Alzheimer's Diseases: State-of-the-Art and Future Perspective of Polymeric Carriers.
    Tonda-Turo C; Origlia N; Mattu C; Accorroni A; Chiono V
    Curr Med Chem; 2018; 25(41):5755-5771. PubMed ID: 29473493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Review of the Common Neurodegenerative Disorders: Current Therapeutic Approaches and the Potential Role of Nanotherapeutics.
    Lamptey RNL; Chaulagain B; Trivedi R; Gothwal A; Layek B; Singh J
    Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Solid lipid nanoparticles as a drug delivery system for the treatment of neurodegenerative diseases.
    Cacciatore I; Ciulla M; Fornasari E; Marinelli L; Di Stefano A
    Expert Opin Drug Deliv; 2016 Aug; 13(8):1121-31. PubMed ID: 27073977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanomaterial based drug delivery systems for the treatment of neurodegenerative diseases.
    Masoudi Asil S; Ahlawat J; Guillama Barroso G; Narayan M
    Biomater Sci; 2020 Aug; 8(15):4109-4128. PubMed ID: 32638706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.